Search Login Register

Venous Thromboembolism Summary

Description: Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.

Also Known As: Thromboembolism, Venous

Networked: 5700 relevant articles (329 outcomes, 1004 trials/studies) for this Disease

Key Drugs and Agents for Venous Thromboembolism

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight) : 95 outcomes 148 studies in 646 results : IBA
  2. Heparin (Liquaemin) : 61 outcomes 91 studies in 537 results : FDA 74 Generic
  3. Warfarin (Coumadin) : 43 outcomes 95 studies in 391 results : FDA 21 Generic
  4. Enoxaparin (Lovenox) : 41 outcomes 122 studies in 333 results : FDA 2 Generic
  5. Anticoagulants : 37 outcomes 74 studies in 479 results : IBA
  6. fondaparinux (Arixtra) : 28 outcomes 46 studies in 183 results : FDA 1
  7. rivaroxaban : 22 outcomes 72 studies in 247 results : IBA
  8. Thrombin : 17 outcomes 30 studies in 137 results : FDA 2
  9. Vitamin K : 16 outcomes 47 studies in 196 results : FDA 6
  10. ximelagatran (Exanta) : 13 outcomes 39 studies in 85 results : IBA
Show All >>

Diseases Related to Venous Thromboembolism

  1. Hemorrhage
  2. Atrial Fibrillation
  3. Neoplasms (Cancer)
  4. Venous Thrombosis (Deep-Vein Thrombosis)
  5. Stroke (Strokes)
Show All >>

Key Therapies for Venous Thromboembolism

Efficacy Chart >>
  1. Arthroplasty : 15 outcomes 48 studies in 271 results
  2. Hip Replacement Arthroplasty (Total Hip Replacement) : 4 outcomes 24 studies in 98 results
  3. Knee Replacement Arthroplasty (Total Knee Replacement) : 4 outcomes 22 studies in 90 results
  4. Vena Cava Filters (Inferior Vena Cava Filter) : 4 outcomes 8 studies in 74 results
  5. Drug Therapy (Chemotherapy) : 3 outcomes 14 studies in 112 results
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.